Compare TNON & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNON | GRDX |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United Kingdom |
| Employees | 27 | 2 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 7.4M |
| IPO Year | N/A | N/A |
| Metric | TNON | GRDX |
|---|---|---|
| Price | $0.78 | $2.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 154.3K | 106.6K |
| Earning Date | 03-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $69.93 | N/A |
| Revenue Next Year | $48.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $1.87 |
| 52 Week High | $3.26 | $5.30 |
| Indicator | TNON | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 39.42 |
| Support Level | $0.72 | $2.03 |
| Resistance Level | $0.91 | $2.56 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 19.96 | 26.09 |
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.